Seattle Genetics Completes Enrollment in Phase 2 Clinical Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer - Associated Press

Seattle Genetics Completes Enrollment in Phase 2 Clinical Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer  Associated Press

This *content* is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.